SPRB Stock Analysis: Buy, Sell, or Hold?
SPRB - Spruce Biosciences, Inc. Common Stock
$43.14
0.31 (0.72%)
▲
5d:
+2.74%
30d:
-17.84%
90d:
-24.69%
HOLD
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When SPRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SPRB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SPRB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$158.30
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$98.29
56.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRB is currently trading at $43.14, which is considered slightly low relative to its 30-day fair value range of $42.83 to $51.75. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.8) compared to its historical average (15.3). Remarkably, the market is currently pricing in an annual earnings decline of 27.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SPRB is in a strong downtrend. Immediate support is located at $40.33, while resistance sits at $46.27.
Market Sentiment: SPRB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $151.00 (+250.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SPRB is in a strong downtrend. Immediate support is located at $40.33, while resistance sits at $46.27.
Market Sentiment: SPRB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $151.00 (+250.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$42.83 -
$51.75
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 250.0% below Wall St target ($151.00)
Trading Range Analysis
30-Day Trading Range
$42.83 -
$51.75
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$40.33
Resistance Level
$46.27
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.84
Wall Street Target
$151.00
(+250.0%)
Revenue Growth (YoY)
-75.9%
Valuation Discount vs History
-27.4% cheaper
PE vs Historical
5.8 vs 15.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-27.4%
(market-implied from PE analysis)
1-Year Target
$38.83
(-10%)
2-Year Target
$34.94
(-19%)
3-Year Target
$31.45
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→15)
$82.36
(+91%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.8 to 15.3
Stabilization Target:
$112.98
(+161.9%)
PE Expansion Potential:
+161.9%
Share & Embed Analysis
Last updated: August 04, 2026 6:22 AM ET
Data refreshes hourly during market hours. Next update: 7:22 AM
Data refreshes hourly during market hours. Next update: 7:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 54 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 61 BUY |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 BUY |
